Vir Biotechnology has signed an agreement that grants the company non-exclusive in-licensed rights to Xencor's Xtend Fc technology to be used to develop a potential therapy for COVID-19. No financial terms of the deal were disclosed.
Forge Therapeutics and Roche have partnered through a licensing agreement for Forge's FG-LpxC LUNG program, a new antibiotic under development for the treatment of severe bacterial lung infections resistant to available drugs.
Researchers from the University of Oxford are working on a novel coronavirus point-of-care molecular diagnostic test that can be done at home and can deliver results within 30 minutes.
Ken Reali has been tapped to serve as CEO of Bioventus, succeeding Tony Bihl, who will be retiring April 20. Reali is a former board member of AdvaMed and AdvaMed Accel, and he also formerly served as the group's ethics and compliance committee chair.
Johnson & Johnson's Janssen Research and Development is collaborating with China-based AmoyDx on a companion diagnostic for an undisclosed cancer therapy. Under the deal, AmoyDx will develop and seek Chinese regulatory approval for its LC10 Essential NGS panel.
Health care workers at the University Hospital San Luigi Gonzaga in Turin, Italy, have been using lung ultrasounds to assess the severity of COVID-19 in the emergency department. The team classifies patients based on the presence of fever, cough or labored breathing, and anyone with just one of those symptoms is moved into isolation for an exam and lung ultrasound to capture early signs of pneumonia, which has been seen even in patients whose symptoms are mild.
The FDA has given expanded emergency use authorization to Quidel's Lyra SARS-CoV-2 test, which can now be used with three more thermocyclers: Roche's LightCycler 480, Qiagen's Rotor-Gene Q and Thermo Fisher Scientific's Applied Biosystems 7500 Standard. European regulators have also given the assay CE mark approval.
The FDA has given its approval to Aegea Medical for its Mara Water Vapor Ablation System used to treat menorrhagia.
A New York district judge has ruled in favor of Novartis and dismissed a whistleblower lawsuit accusing the drugmaker of paying kickbacks to doctors through "sham" speaker fees to boost prescriptions of its multiple sclerosis drug Gilenya. The suit was dismissed due to insufficient "detailed allegations and representative examples."